These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35130946)

  • 1. Statistical analysis plan for the OPTIMUM study: optimising immunisation using mixed schedules, an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule.
    Totterdell JA; Chacon GP; Estcourt MJ; Jones M; Richmond P; Snelling TL; Marsh JA
    Trials; 2022 Feb; 23(1):121. PubMed ID: 35130946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OPTIMUM study protocol: an adaptive randomised controlled trial of a mixed whole-cell/acellular pertussis vaccine schedule.
    Perez Chacon G; Estcourt MJ; Totterdell J; Campbell DE; Perrett KP; Marsh JA; Richmond PC; Wood N; Gold MS; Holt PG; Waddington CS; Snelling TL
    BMJ Open; 2020 Dec; 10(12):e042838. PubMed ID: 33334840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ORVAC trial: a phase IV, double-blind, randomised, placebo-controlled clinical trial of a third scheduled dose of Rotarix rotavirus vaccine in Australian Indigenous infants to improve protection against gastroenteritis: a statistical analysis plan.
    Jones MA; Graves T; Middleton B; Totterdell J; Snelling TL; Marsh JA
    Trials; 2020 Aug; 21(1):741. PubMed ID: 32843086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy and the risk of IgE-mediated food allergy among Australian children.
    Estcourt MJ; Marsh JA; Campbell DE; Gold MS; Allen KJ; Richmond P; Waddington CS; Snelling TL
    BMJ Open; 2018 Jan; 8(1):e020232. PubMed ID: 29391374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth: A Randomized Clinical Trial.
    Wood N; Nolan T; Marshall H; Richmond P; Gibbs E; Perrett K; McIntyre P
    JAMA Pediatr; 2018 Nov; 172(11):1045-1052. PubMed ID: 30208475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantity and Quality of Antibodies After Acellular Versus Whole-cell Pertussis Vaccines in Infants Born to Mothers Who Received Tetanus, Diphtheria, and Acellular Pertussis Vaccine During Pregnancy: A Randomized Trial.
    Wanlapakorn N; Maertens K; Vongpunsawad S; Puenpa J; Tran TMP; Hens N; Van Damme P; Thiriard A; Raze D; Locht C; Poovorawan Y; Leuridan E
    Clin Infect Dis; 2020 Jun; 71(1):72-80. PubMed ID: 31418814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pertussis immunisation in infancy and atopic outcomes: A protocol for a population-based cohort study using linked administrative data.
    Pérez Chacón G; Fathima P; Jones M; Barnes R; Richmond PC; Gidding HF; Moore HC; Snelling TL
    PLoS One; 2021; 16(12):e0260388. PubMed ID: 34874968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential T- and B-cell responses to pertussis in acellular vaccine-primed versus whole-cell vaccine-primed children 2 years after preschool acellular booster vaccination.
    Schure RM; Hendrikx LH; de Rond LG; Oztürk K; Sanders EA; Berbers GA; Buisman AM
    Clin Vaccine Immunol; 2013 Sep; 20(9):1388-95. PubMed ID: 23825195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimising DTwP-containing vaccine infant immunisation schedules (OptImms) - a protocol for two parallel, open-label, randomised controlled trials.
    Kelly S; Liu X; Theiss-Nyland K; Voysey M; Murphy S; Li G; Nyantaro M; Gurung M; Basnet S; Pokhrel B; Bijukchhe SM; Eordogh A; Gombe B; Kakande A; Kerridge S; Kimbugwe G; Kusemererwa S; Lubyayi L; Luzze H; Mazur O; Mujadidi YF; Nabukenya S; Nagumo WR; Nareeba T; Noristani R; O'Reilly P; Roberts A; Shah G; Shrestha S; Shrestha LP; Thapa SB; Kibengo FM; Sharma AK; Elliott A; Shrestha S; Pollard AJ
    Trials; 2023 Jul; 24(1):465. PubMed ID: 37480110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
    Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
    J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infant Whole-Cell Versus Acellular Pertussis Vaccination in 1997 to 1999 and Risk of Childhood Hospitalization for Food-Induced Anaphylaxis: Linked Administrative Databases Cohort Study.
    Pérez Chacón G; Fathima P; Jones M; Estcourt MJ; Gidding HF; Moore HC; Richmond PC; Snelling T
    J Allergy Clin Immunol Pract; 2024 Mar; 12(3):670-680. PubMed ID: 38182097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimising the timing of whooping cough immunisation in mums (OpTIMUM) through investigating pertussis vaccination in pregnancy: an open-label, equivalence, randomised controlled trial.
    Calvert A; Amirthalingam G; Andrews N; Basude S; Coleman M; Cuthbertson H; England A; Greening V; Hallis B; Johnstone E; Jones CE; Karampatsas K; Khalil A; Le Doare K; Matheson M; Peregrine E; Snape MD; Vatish M; Heath PT;
    Lancet Microbe; 2023 May; 4(5):e300-e308. PubMed ID: 37080224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trial.
    Pitisuttithum P; Chokephaibulkit K; Sirivichayakul C; Sricharoenchai S; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chauhan M; Wijagkanalan W; Hommalai G; Fortuna L; Chinwangso P; Poredi IK; van den Biggelaar AHJ; Pham HT; Viviani S
    Lancet Infect Dis; 2018 Nov; 18(11):1260-1268. PubMed ID: 30266329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.
    Sricharoenchai S; Sirivichayakul C; Chokephaibulkit K; Pitisuttithum P; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chinwangso P; Poredi IK; Petre J; Thai PH; Viviani S
    Lancet Infect Dis; 2018 Jan; 18(1):58-67. PubMed ID: 29066131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised controlled trial.
    Barug D; Pronk I; van Houten MA; Versteegh FGA; Knol MJ; van de Kassteele J; Berbers GAM; Sanders EAM; Rots NY
    Lancet Infect Dis; 2019 Apr; 19(4):392-401. PubMed ID: 30938299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-cell or acellular pertussis vaccination in infancy determines IgG subclass profiles to DTaP booster vaccination.
    van der Lee S; Sanders EAM; Berbers GAM; Buisman AM
    Vaccine; 2018 Jan; 36(2):220-226. PubMed ID: 29199041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-Cell Pertussis Vaccination and Decreased Risk of IgE-Mediated Food Allergy: A Nested Case-Control Study.
    Estcourt MJ; Campbell DE; Gold MS; Richmond P; Allen KJ; Quinn HE; Marsh JA; Peters RL; Valerio C; Dai D; Waddington CS; Wood NJ; McIntyre PB; Holt PG; Snelling TL
    J Allergy Clin Immunol Pract; 2020 Jun; 8(6):2004-2014. PubMed ID: 31891824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allergic disease at the age of 7 years after pertussis vaccination in infancy: results from the follow-up of a randomized controlled trial of 3 vaccines.
    Nilsson L; Kjellman NI; Bjorksten B
    Arch Pediatr Adolesc Med; 2003 Dec; 157(12):1184-9. PubMed ID: 14662571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-Cell or Acellular Pertussis Primary Immunizations in Infancy Determines Adolescent Cellular Immune Profiles.
    van der Lee S; Hendrikx LH; Sanders EAM; Berbers GAM; Buisman AM
    Front Immunol; 2018; 9():51. PubMed ID: 29416544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial.
    Martinón-Torres F; Halperin SA; Nolan T; Tapiéro B; Perrett KP; de la Cueva IS; García-Sicilia J; Stranak Z; Vanderkooi OG; Kosina P; Rumlarova S; Virta M; Arribas JMM; Miranda-Valdivieso M; Novas BA; Bozensky J; Ortega MJC; Amador JTR; Baca M; Palomino EE; Zuccotti GV; Janota J; Marchisio PG; Kostanyan L; Meyer N; Ceregido MA; Cheuvart B; Kuriyakose SO; Mesaros N
    Vaccine; 2021 Mar; 39(11):1598-1608. PubMed ID: 33612341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.